What is Cystourethroscopic Insertion of a Urolift Implant?
Cystourethroscopic insertion of a Urolift implant (Prostatic Urethral Lift/PUL) is a minimally invasive procedure performed under cystoscopic visualization where small permanent implants are placed transurethrally into the lateral prostatic lobes to mechanically retract obstructing tissue and open the prostatic urethra, treating lower urinary tract symptoms from benign prostatic hyperplasia.
Procedure Overview
The technique involves placing UroLift implants through a cystoscope to literally "hold open" the lateral prostatic lobes, creating a passage through the obstructed prostatic urethra 1, 2. The procedure:
- Can be performed entirely under local anesthesia (instillation of lidocaine gel into the urethra 15 minutes before the procedure) 3
- Takes approximately 10 minutes of operating time 3
- Typically requires placement of an average of 4-5 implants 1
- Involves rigid cystoscopy with transurethral delivery of permanent implants 4
Patient Selection Criteria
According to AUA guidelines, PUL may be offered to patients with LUTS attributed to BPH provided:
- Prostate volume <80g
- Verified absence of an obstructive middle lobe 5
The most recent European guidelines emphasize selecting patients who meet specific criteria for optimal outcomes 6:
- Age <74 years
- Low comorbidity burden
- Impaired quality of life (QoL score >4)
- Slow urinary stream (Qmax <10 ml/s)
- Predominance of obstructive symptoms
- Symptom burden (IPSS >16)
Clinical Outcomes
The L.I.F.T. randomized controlled trial demonstrated 4:
- IPSS reduction from 22.1 at baseline to 11.1 at 12 months (p<0.001)
- Peak flow rate increase of 4.0 ml/s sustained at 12 months (p<0.001)
- Symptom improvement evident by 2 weeks and sustained through 1 year
- No occurrence of de novo ejaculatory or erectile dysfunction
Key Advantages
The procedure offers several benefits that distinguish it from traditional TURP:
- Preservation of sexual function - no retrograde ejaculation reported 1, 4
- Rapid recovery - patients return to normal activity quickly 7
- Office-based capability - can be done under local anesthesia without general anesthesia 3, 2
- Minimal perioperative complications - adverse events typically mild and transient 4, 7
Important Caveats
Contraindications and limitations:
- Not suitable for patients with obstructive median lobes 5
- Prostate volume must be <80g 5
- Retreatment rate of approximately 6.5% progressing to TURP within the first year 1
- Creates significant MRI artifacts that can obscure 32% of the gland on diffusion-weighted imaging, particularly affecting the mid-basal transition zone, which may complicate future prostate cancer surveillance 8
Patients considering this procedure should be counseled about the impact on future prostate MRI quality if they are at risk for prostate cancer or require ongoing surveillance 8.
Clinical Context
The procedure represents a middle ground between medical management and traditional surgical resection, particularly valuable for patients who desire preservation of erectile and ejaculatory function or prefer avoiding general anesthesia 5. The AUA guideline gives it a Moderate Recommendation with Grade C evidence 5.